-
2024-517300-10-01
5
2020-12-17
Resectable diffuse type gastric and gastroesophageal junction Typ II/I
-
2024-514383-61-00
6
2020-07-07
Diarrhoea predominant irritable bowel syndrome
-
2024-514892-16-00
6
2020-05-05
Diarrhoea predominant irritable bowel syndrome
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-512104-19-00
6
2019-11-19
Irritable Bowel Syndrome
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-520521-21-00
5
2025-09-02
Hyperlipidemia
-
2023-506880-32-01
1
2025-04-14
Pulmonary Disease, Chronic Obstructive
-
2024-517199-39-00
4
2025-03-19
COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYNDROME
-
2024-515905-25-00
5
2025-01-29
Overweight or Obesity
-
2023-508932-68-00
4
2024-11-14
Diabetic Peripheral Neuropathic Pain
-
2022-501457-37-00
5
2024-10-28
Myeloid Leukemia in Children with Down Syndrome
-
2023-503383-17-01
5
2024-10-10
Female androgenetic alopecia
-
2023-506668-15-00
5
2024-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-505435-12-00
5
2024-06-04
Asthma
-
2024-510966-18-00
4
2024-06-03
Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
-
2023-506906-38-00
5
2024-05-23
Follicular Lymphoma
-
2022-500571-32-00
4
2024-05-15
Early-Stage Unfavorable Classical Hodgkin Lymphoma
-
2024-513462-19-00
5
2023-03-30
Refractory Chronic Cough, Including Unexplained Chronic Cough
-
2023-509825-38-00
5
2022-12-01
Metastatic Non–Small Cell Lung Cancer